Hybrid risk adjustment for pharmaceutical benefits

Welcome to the UPF Digital Repository

García-Goñi, Manuel; Ibern, Pere; Inoriza, José María. Hybrid risk adjustment for pharmaceutical benefits. 2009
To cite or link this document: http://hdl.handle.net/10230/4592
dc.contributor.author García-Goñi, Manuel
dc.contributor.author Ibern, Pere
dc.contributor.author Inoriza, José María
dc.contributor.other Universitat Pompeu Fabra. Departament d'Economia i Empresa
dc.date.issued 2009-01-01
dc.identifier.uri http://hdl.handle.net/10230/4592
dc.description.abstract This paper analyses the application of hybrid risk adjustment versus either prospective or concurrent risk adjustment formulae in the context of funding pharmaceutical benefits for the population of an integrated healthcare delivery organization in Catalonia during years 2002 and 2003. We apply a mixed formula and find that a hybrid risk adjustment model increases incentives for efficiency in the provision of low risk individuals at health organizations not only as a whole but also at each internal department compared to only prospective models by reducing within-group variation of drug expenditures.
dc.language.iso eng
dc.relation.ispartofseries Economics and Business Working Papers Series; 1139
dc.rights L'accés als continguts d'aquest document queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.title Hybrid risk adjustment for pharmaceutical benefits
dc.type info:eu-repo/semantics/workingPaper
dc.date.modified 2016-06-04T02:51:05Z
dc.subject.keyword Labour, Public, Development and Health Economics
dc.subject.keyword drug expenditure
dc.subject.keyword hybrid risk-adjustment
dc.subject.keyword morbidity
dc.subject.keyword clinical risk groups
dc.rights.accessRights info:eu-repo/semantics/openAccess

See full text
This document is licensed under a Creative Commons license:


Advanced Search


My Account